ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-10T15223
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Acute Myeloid Leukemia AML Biomarker Testing Market Insights Forecast to 2029
BUY CHAPTERS

Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Research Report 2025

Code: QYRE-Auto-10T15223
Report
January 2025
Pages:77
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Abbott Laboratories
Novartis
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics
BioMerieux SA
Skyline DX B.V.

Acute Myeloid Leukemia (AML) Biomarker Testing Market

The global market for Acute Myeloid Leukemia (AML) Biomarker Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Acute Myeloid Leukemia (AML) biomarker testing is a diagnostic and prognostic approach that involves the analysis of specific biological markers or genetic alterations in the cells of a patient with AML, a type of blood cancer that affects the bone marrow and blood. Biomarkers in AML testing are used to help diagnose the disease, classify subtypes, guide treatment decisions, and assess the prognosis of AML patients. These markers can be found in the AML cells themselves or in the surrounding bone marrow environment.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Biomarker Testing.
The Acute Myeloid Leukemia (AML) Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Myeloid Leukemia (AML) Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia (AML) Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Acute Myeloid Leukemia (AML) Biomarker Testing Market Report

Report Metric Details
Report Name Acute Myeloid Leukemia (AML) Biomarker Testing Market
Segment by Type
  • Genetic Acute Myeloid Leukemia (AML) Biomarker
  • Epigenetic Acute Myeloid Leukemia (AML) Biomarker
  • Proteomic Acute Myeloid Leukemia (AML) Biomarker
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA, Skyline DX B.V.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Acute Myeloid Leukemia (AML) Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Acute Myeloid Leukemia (AML) Biomarker Testing Market report?

Ans: The main players in the Acute Myeloid Leukemia (AML) Biomarker Testing Market are Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA, Skyline DX B.V.

What are the Application segmentation covered in the Acute Myeloid Leukemia (AML) Biomarker Testing Market report?

Ans: The Applications covered in the Acute Myeloid Leukemia (AML) Biomarker Testing Market report are Hospitals, Cancer diagnostic Centers, Research Institutes, Others

What are the Type segmentation covered in the Acute Myeloid Leukemia (AML) Biomarker Testing Market report?

Ans: The Types covered in the Acute Myeloid Leukemia (AML) Biomarker Testing Market report are Genetic Acute Myeloid Leukemia (AML) Biomarker, Epigenetic Acute Myeloid Leukemia (AML) Biomarker, Proteomic Acute Myeloid Leukemia (AML) Biomarker

Recommended Reports

Leukemia & Hematology

Biomarker & Diagnostic

Hematology Equipment

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Genetic Acute Myeloid Leukemia (AML) Biomarker
1.2.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
1.2.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Cancer diagnostic Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Perspective (2020-2031)
2.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Region (2020-2025)
2.2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2026-2031)
2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Dynamics
2.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Trends
2.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
2.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges
2.3.4 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue (2020-2025)
3.1.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Players (2020-2025)
3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue
3.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2024
3.5 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing Head office and Area Served
3.6 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Product and Application
3.7 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Type (2020-2025)
4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2026-2031)
5 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Application (2020-2025)
5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2020-2031)
6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025)
6.4 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2020-2031)
7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025)
7.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2020-2031)
8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2020-2031)
9.2 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025)
9.4 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2020-2031)
10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.1.4 Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.2.4 Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.3.4 Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Cancer Genetics Inc.
11.4.1 Cancer Genetics Inc. Company Details
11.4.2 Cancer Genetics Inc. Business Overview
11.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.4.4 Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.4.5 Cancer Genetics Inc. Recent Development
11.5 Sysmex Corporation
11.5.1 Sysmex Corporation Company Details
11.5.2 Sysmex Corporation Business Overview
11.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.5.4 Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.5.5 Sysmex Corporation Recent Development
11.6 Epigenomics AG
11.6.1 Epigenomics AG Company Details
11.6.2 Epigenomics AG Business Overview
11.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.6.4 Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.6.5 Epigenomics AG Recent Development
11.7 BioMerieux SA
11.7.1 BioMerieux SA Company Details
11.7.2 BioMerieux SA Business Overview
11.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.7.4 BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.7.5 BioMerieux SA Recent Development
11.8 Skyline DX B.V.
11.8.1 Skyline DX B.V. Company Details
11.8.2 Skyline DX B.V. Business Overview
11.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.8.4 Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.8.5 Skyline DX B.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Abbott Laboratories
Novartis
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics
BioMerieux SA
Skyline DX B.V.
List of Tables
 Table 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Genetic Acute Myeloid Leukemia (AML) Biomarker
 Table 3. Key Players of Epigenetic Acute Myeloid Leukemia (AML) Biomarker
 Table 4. Key Players of Proteomic Acute Myeloid Leukemia (AML) Biomarker
 Table 5. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2020-2025)
 Table 9. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2026-2031)
 Table 11. Acute Myeloid Leukemia (AML) Biomarker Testing Market Trends
 Table 12. Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
 Table 13. Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges
 Table 14. Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
 Table 15. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players (2020-2025)
 Table 17. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2024)
 Table 18. Ranking of Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Headquarters and Area Served
 Table 21. Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Product and Application
 Table 22. Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2020-2025)
 Table 26. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2026-2031)
 Table 28. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2020-2025)
 Table 30. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2026-2031)
 Table 32. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Abbott Laboratories Company Details
 Table 48. Abbott Laboratories Business Overview
 Table 49. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 50. Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 51. Abbott Laboratories Recent Development
 Table 52. Novartis AG Company Details
 Table 53. Novartis AG Business Overview
 Table 54. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 55. Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 56. Novartis AG Recent Development
 Table 57. Thermo Fisher Scientific Company Details
 Table 58. Thermo Fisher Scientific Business Overview
 Table 59. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 60. Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 61. Thermo Fisher Scientific Recent Development
 Table 62. Cancer Genetics Inc. Company Details
 Table 63. Cancer Genetics Inc. Business Overview
 Table 64. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 65. Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 66. Cancer Genetics Inc. Recent Development
 Table 67. Sysmex Corporation Company Details
 Table 68. Sysmex Corporation Business Overview
 Table 69. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 70. Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 71. Sysmex Corporation Recent Development
 Table 72. Epigenomics AG Company Details
 Table 73. Epigenomics AG Business Overview
 Table 74. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 75. Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 76. Epigenomics AG Recent Development
 Table 77. BioMerieux SA Company Details
 Table 78. BioMerieux SA Business Overview
 Table 79. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 80. BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 81. BioMerieux SA Recent Development
 Table 82. Skyline DX B.V. Company Details
 Table 83. Skyline DX B.V. Business Overview
 Table 84. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product
 Table 85. Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 86. Skyline DX B.V. Recent Development
 Table 87. Research Programs/Design for This Report
 Table 88. Key Data Information from Secondary Sources
 Table 89. Key Data Information from Primary Sources
 Table 90. Authors List of This Report


List of Figures
 Figure 1. Acute Myeloid Leukemia (AML) Biomarker Testing Picture
 Figure 2. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Type: 2024 VS 2031
 Figure 4. Genetic Acute Myeloid Leukemia (AML) Biomarker Features
 Figure 5. Epigenetic Acute Myeloid Leukemia (AML) Biomarker Features
 Figure 6. Proteomic Acute Myeloid Leukemia (AML) Biomarker Features
 Figure 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Application: 2024 VS 2031
 Figure 9. Hospitals Case Studies
 Figure 10. Cancer diagnostic Centers Case Studies
 Figure 11. Research Institutes Case Studies
 Figure 12. Others Case Studies
 Figure 13. Acute Myeloid Leukemia (AML) Biomarker Testing Report Years Considered
 Figure 14. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region: 2024 VS 2031
 Figure 17. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players in 2024
 Figure 18. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2024
 Figure 20. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2020-2031)
 Figure 22. United States Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2020-2031)
 Figure 26. Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2020-2031)
 Figure 34. China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2020-2031)
 Figure 42. Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2020-2031)
 Figure 46. Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Abbott Laboratories Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 50. Novartis AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 52. Cancer Genetics Inc. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 53. Sysmex Corporation Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 54. Epigenomics AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 55. BioMerieux SA Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 56. Skyline DX B.V. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global AML Screening Market Research Report 2024
Acute Myeloid Leukemia AML Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tumor Biomarker Test Market Research Report 2024
Global Imaging Biomarker Market Research Report 2025
Global Alzheimer s Disease Biomarker Market Research Report 2024
Hematologic Malignancies Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematology Testing Product Market Research Report 2024
Oncology Blood Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Genomic Biomarkers Market Research Report 2024
Global Infectious Disease Biomarker Testing Market Research Report 2024
Global Biomarkers for Signing Cancer Market Research Report 2025
Acute Myeloid Leukemia Biomarker Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Myeloid Leukemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Leukemia Molecular Diagnostics Market Research Report 2024
Acute Lymphocytic Leukemia Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Oncology Testing Market Research Report 2024
Global Haemato Oncology Testing Market Research Report 2025
Global Cancer Genomic Testing Market Research Report 2024
Global Genomic Testing in Cancer Market Research Report 2024
Global Cardiac Biomarkers Testing Device Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions